While the reduction in price target could suggest a more cautious outlook on Acurx Pharmaceuticals' future stock price performance, the maintenance of a Buy rating indicates a continued positive view on the company's fundamentals. This mixed signal could lead to a neutral short-term impact on the stock price as investors weigh the lowered price target against the ongoing endorsement.